Guotai Asset Management sees China innovative drug rally as event-driven rebound after pullback

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • Guotai Asset Management flagged a sharp rebound in China’s innovative-drug and CXO complex, with tracked indices up more than 4% at the close. * WCLC clinical updates drove sentiment, led by stronger interim overall-survival results for a PD-1/VEGF bispecific in first-line NSCLC. * Positive interim Phase III readouts for a B7H3 ADC in second-line SCLC reinforced “ADC plus lung cancer” positioning, supporting licensing expectations. * The firm expects CXO demand to hold up as peptides, ADCs, and complex small molecules move into commercial stockpiling and supply. * Guotai sees higher near-term earnings visibility into third-quarter results, while warning macro volatility could disrupt the trade. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guotai Asset Management Co. Ltd. published the original content used to generate this news brief on September 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.